AI Article Synopsis
- New therapies for geographic atrophy (GA) are now available, allowing for better management in clinical settings.
- A living systematic review found that inhibiting complement factors C3 and C5 may reduce the growth of GA over 12 and 24 months, with little difference in side effects compared to sham treatments.
- However, these treatments do not seem to improve visual acuity significantly and may lead to more ocular adverse effects and new cases of neovascular age-related macular degeneration.
Article Abstract
With the introduction of therapies to treat geographic atrophy (GA), GA management in clinical practice is now possible. A living systematic review can provide access to timely and robust evidence synthesis. This review found that complement factor 3 and 5 (C3 and C5) inhibition compared to sham likely reduces change in square root GA area at 12 months and untransformed GA area at 24 months. There is likely little to no difference in the rate of systemic treatment-emergent adverse events compared to sham. C3 and C5 inhibition, however, likely does not improve best-corrected visual acuity (BCVA) at 12 months, and the evidence is uncertain regarding change in BCVA at 24 months. Higher rates of ocular treatment emergent adverse effects with complement inhibition occur at 12 months and likely at 24 months. Complement inhibition likely results in new onset neovascular age-related macular degeneration at 12 months. This living meta-analysis will continuously incorporate new evidence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.survophthal.2023.11.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!